The maximum potential market for dengue drugs V 1.0

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 203-212

  Dow, Geoffrey ^a   Mora, Eric ^b  

^a 60 Pharmaceuticals LLC   (United States)

^b PreSight Healthcare Solutions   (United States)

Author keywords

Dengue; Dengue drug; Dengue vaccine; Economic burden; Market; Tiered pricing

Indexed keywords

DENGUE VACCINE; PNEUMOCOCCUS VACCINE; YELLOW FEVER VACCINE;

AMBULATORY CARE; ARTICLE; COST CONTROL; DENGUE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; GROSS NATIONAL PRODUCT; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MONTE CARLO METHOD; PRIORITY JOURNAL; SEROTYPE; VACCINATION;

ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; DENGUE; DRUG UTILIZATION; HUMANS;

EID: 84867236838     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.08.011     Document Type: Article

References (22)

1. Amarasinghe A., Mahoney R.T. Estimating demand and supply of dengue vaccine in Brazil. Hum. Vaccine 2011, 7(7):776-780.
2. Armien B., Suaya J.A., Sah B.K., Barvard V., Marchena L., Campos C., Shepard D.S. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am. J. Trop. Med. Hyg. 2008, 79:364-371.
3. Beatty M.E., Beutels P., Meltzer M.I., Shepard D.S., Hombach J., Hutubessy R., Dessis D., Coudeville L., Dervaux B., Wichmann O., Margolis H.S., Kuritsky J.N. Health economics of dengue: a systematic literature review and expert panel's assessment. Am. J. Trop. Med. Hyg. 2011, 84(3):473-488.
4. Coller B.G., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus-induced disease. Vaccine 2011, 29(42):7267-7275.
5. Congressional Budget Office, 2006. Research and development in the pharmaceutical industry. Publication # 2859, Congress of the United States.
6. Danko J.R., Beckett C.G., Porter K.R. Development of dengue DNA vaccines. Vaccine 2011, 29(42):7261-7266.
7. Di Masi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22:151-185.
8. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify for inclusion in a live attenuated DENV vaccine. Vaccine 2011, 29(42):7242-7250.
9. Guy B., Barrere B., Malnowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:5860-5868.
10. IFPMA Data exclusivity: Encouraging the Development of New Medicines 2011, IFPMA, Geneva.
11. Mahoney R.T., Francis D.P., Frazatti-Gallina N.M., Precioso A.R., Watier P., Whitehead P., Whitehead S.S. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butanten, Sao Paulo, Brazil. Vaccine 2012, 30(32):4892-4896.
12. Moon S., Jambert E., Childs M., von Schoen-Angerer T. A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Globalization Health 2011, 7(1):39.
13. Osorio J.E., Huange C.Y.H., Kinney R.M., Stinchcomb X.X. Development of DENVax: A chmieric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29(42):7251-7260.
14. Sanofi, 2009. Press release - May 12, 2009: Sanofi-Aventis builds a new plant vaccine manufacturing facility in France with an investment of 350million Euros. Accessed 8/15/12 online at <>. http://www.sanofipasteur.com/EN/media/press-tool-kits/focus-on-dengue.html.
15. Sanofi, 2012. Press release - July 25, 2012: Sanofi-Pasteur's dengue vaccine demonstrates proof of efficacy. <> (accessed 8/15/12). http://www.en.sanofi.com/Images/30784_20120725_SP-Dengue-vaccine_en.pdf.
16. Shepard D.S., Suaya J.A., Halstead S.B., Nathan M.B., Gubler D.J., Mahoney R.T., Wang D.N.C., Meltzer M.I. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 2004, 22(9-10):1275-1280.
17. Suaya J.A., Shepard D.S., Siqueirra J.B., Martelli C.T., Lum L.C.S., Tan L.H., Kongsin S., Jiamton S., Garrido F., Montoya R., Amien B., Huy R., Castillo L., Caram M., Sah B.K., Sughayyar R., Tyo K.R., Halstead S.B. Cost of dengue cases in eight countries in the Americas and Asia: a prospective Study. Am. J. Trop. Med. Hyg. 2009, 80(5):846-855.
18. TDR Dengue: Guidelines for Diagnosis, Prevention, Treatment and Control 2009, World Health Organization, Geneva.
19. Tren R., Bate R., Hess K., Ayodele T., Cudjoe F. The Global Funds' Malaria Medicine Subsidy: A Nice Idea With Nasty Implications 2011, Africa Fighting Malaria, Washington DC.
20. WHO, 2012. Fact Sheet 117: Dengue and severe dengue. <> (accessed 3/22/12). http://www.who.int/mediacentre/factsheets/fs117/en/.
21. WHO, 2012b. Diseased covered by NTD department. <> (accessed 8/15/12). http://www.who.int/neglected_diseases/diseases/en/.
22. Zemmel R., Shiekh M. Invention reinvented: McKinsey perspectives on pharmaceutical R&D 2010, McKinsey and Company.